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Abstract
Background: Nelfinavir is an HIV protease inhibitor that has been used for a long period of time to treat HIV-
infected individuals. It has recently emerged that nelfinavir could represent a prospective new anti-cancer drug,
prompting us to test the effect of nelfinavir on leukemia cells.
Methods: By combining in vitro and ex vivo studies, the effect of nelfinavir on leukemia cells and non-malignant,
bone marrow-derived tissue cells was analyzed.
Results: At a concentration of 9 μg/ml, nelfinavir induced death of 90% of HL60, IM9, and Jurkat cells. At the same
concentration and treatment conditions, less than 10% of aspirated human bone marrow cells showed nelfinavir-
induced cell damage. Nelfinavir-induced death of leukemia cells was accompanied by activation of caspases 3, 7,
and 8. Despite caspase activation, the upregulation of the anti-apoptotic bcl-2 family member protein mcl-1 that
resulted from nelfinavir treatment stabilized the mitochondrial membrane potential, resulting in primarily
mitochondria-independent cell death. Pharmacological downregulation of mcl-1 expression by treatment with
sorafenib (2 μg/ml) significantly enhanced nelfinavir-induced apoptosis even at lower nelfinavir concentrations (5
μg/ml), but did not have additional detrimental effects on non-malignant bone marrow cells.
Conclusions: The ability of nelfinavir to induce apoptosis in leukemia cells as a single agent in a mitochondria-
independent manner might suggest it could be used as a second or third line of treatment for leukemia patients
for whom standard mitochondria-directed treatment strategies have failed. Combination treatment with nelfinavir
and sorafenib might further enhance the efficacy of nelfinavir even on chemo-resistant leukemia cells.
Background
Blood cancer cells are highly sensitive to cytostatic drugs
but, depending on the cancer type, often become resis-
tant after initial therapy, necessitating second and even
third line treatment therapies. Thus, there is a need for
additional new anti-cancer drugs that induce specific
cell death pathways in leukemia cells. It has recently
been shown that the HIV protease inhibitor nelfinavir
(Viracept®) can induce cell death in a variety of human
cancer types [1,2], and clinical studies with nelfinavir are
currently proposed or underway [3-6]. Nelfinavir
appears to induce cell death in human cancer cells by
rather pleiotropic mechanisms, including apoptosis,
necrosis, and autophagy [1,2]. Swelling of the endoplas-
mic reticulum by an accumulation of misfolded proteins
(ER stress response) appears to be a central mechanism
in nelfinavir induced death in several cancer types,
including lung cancer [1], glioma [2], and ovarian cancer
cells [7,8], and precedes the activation of apoptosis.
Apoptosis can be induced by several pathways, includ-
ing an extrinsic pathway mediated by cell membrane-
bound death receptors and an intrinsic pathway
mediated by activation of pro-apoptotic intracellular
mechanisms [9]. Mitochondria play a central role in the
induction and control of apoptosis because they harbour
* Correspondence: ansgar.bruening@med.uni-muenchen.de
Ludwig-Maximilians University Munich, Department of Obstetrics/
Gynaecology, Molecular Biology Laboratory, Munich, Germany
Brüning et al. Molecular Cancer 2010, 9:19
http://www.molecular-cancer.com/content/9/1/19
© 2010 Brüning et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.several apoptosis-inducing proteins within their mem-
branes that can be released into the cytosol (cytochrome
c, smac/DIABLO) to induce caspase-dependent cell
death [9,10]. Release of these mitochondrial factors
occurs via outer mitochondrial membrane pore forma-
tion by pro-apoptotic bcl-2 family members, such as
bax, bak and t-bid. The activities of these pro-apoptotic
molecules are counterbalanced by the anti-apoptotic
mitochondrial membrane proteins bcl-2, bcl-XL, and
mcl-1 [9-12]. Although there are several different the-
ories regarding how the pro- and anti-apoptotic bcl-2
family members interact [11,12], it has repeatedly been
shown and is generally believed that increased expres-
sion of pro-apoptotic bcl-2 family members promotes
cell death, whereas increased expression of anti-apopto-
tic bcl-2 family members facilitates cell survival. The
most prominent anti-apoptotic bcl-2 family members,
including bcl-2 (B-cell CLL/lymphoma 2), bcl-XL
(BCL2L1) and mcl-1 (myeloid cell leukemia 1; BCL2L3),
were originally identified and found to be over-
expressed in leukemia cells [13,14]. Mcl-1 is a rather
unique member of the bcl-2 family in that it has a rela-
tively large molecular weight of 40/42 kDa, compared to
the molecular weight of ca. 26 kDa common to most
other bcl-2 family members. Mcl-1 is a target of several
pro-apoptotic proteins and has been shown to undergo
caspase-mediated degradation during apoptosis [15].
Further, a shorter splice form of mcl-1 (mcl-1s; 36 kDa)
has been described and has been shown to exert a pro-
apoptotic function [16]. Thus, expression and modifica-
tion of mcl-1 appears to be crucial for regulation of cell
survival and cell death in leukemia cells [17,18]. In the
present study, we show that despite its ability to induce
apoptosis, nelfinavir enhances expression of the mito-
chondria-protective mcl-1 protein in leukemia cells,
resulting in a primarily mitochondria-independent cas-
pase activation and cell death.
Methods
Cells and cell culture
The human leukemia cell lines Jurkat (acute T-cell leu-
kemia, ATCC TIB-152), HL-60 (acute promyelocytic
leukemia, ATCC CCL-240) and IM-9 (EBV-transformed
B-lymphoblastoid, ATCC. CCL 159) were cultured in
RPMI-1640 medium supplemented with 10% fetal calf
serum and antibiotics at 37°C in a humidified atmo-
sphere with 5% CO2. All cell culture reagents were from
PAA, Pasching, Austria. Stromal bone marrow cells,
enriched by Ficoll gradient centrifugation as described
[19], were kindly provided by the Tumour Immunology
Department of the University Hospital, Munich. Bone
marrow fibroblasts were generated by allowing bone
marrow cells to adhere to plastic cell culture flasks.
Cells were grown for 4 weeks, and non-adherent cells
w e r er e g u l a r l yd i s p l a c e db yr e p l a c i n gt h ec e l lc u l t u r e
medium. Cells exhibited a typical fibroblast-like mor-
phology, and fibroblasts appeared to be the only cell
type from bone marrow cells that showed significant
proliferation under the cell culture conditions used.
Drugs and drug treatment
Nelfinavir mesylate (Viracept®; MW 663,90) was gener-
ously provided by Pfizer, Groton, CT, USA. Nelfinavir
was dissolved in DMSO and stored at -20°C as a 50 mg/
ml stock solution. The primary concentration used in
this study was 8 μg/ml nelfinavir mesylate, correspond-
ing to a molar concentration of 12 μM. Sorafenib
(Axxora, Lörrach, Germany) was stored as a 25 mg/ml
stock solution in DMSO. In control experiments, cells
received an amount of DMSO equal to that used in the
treated cells. Staurosporine (Sigma, Munich, Germany)
was stored as a 500 μM stock solution in DMSO.
Chemosensitivity assay (ATP-TCA assay)
To test the viability of the cancer cells, 5000 cells in a
total volume of 200 μl were plated in flat-bottomed 96-
well plates (Nunc, Wiesbaden, Germany) and incubated
with nelfinavir for 48 h at 37°C. For cell extraction, 50
μl tumour cell extraction buffer (DCS Innovative Diag-
nostik-Systems, Hamburg, Germany) was added to each
well, mixed thoroughly, and incubated for 20 minutes at
room temperature. Using a MicroLumat LB 96P biolu-
minometer (EG&G Berthold, Bad Wildbad, Germany),
Luciferin-Luciferase agent (DCS Innovative Diagnostik-
Systems, Hamburg, Germany) was added automatically
to each sample and samples were analyzed for
bioluminescence.
Annexin binding assay
FITC-labelled annexin V (Biocat, Heidelberg, Germany)
was added to viable cells as recommended by the sup-
plier in combination with propidium iodide, and cells
were analyzed with a FACScan using an FL-1 setting
(propidium iodide) at 575 nm and an FL-2 setting
(FITC) at 530 nm. FACScan analysis was performed
using a Becton Dickinson FACScan analyzer (Becton
Dickinson, Heidelberg, Germany).
Cell cycle analysis
For cell cycle analysis, leukemia cells were washed with
phosphate-buffered saline (PBS), fixed with 70% metha-
nol, incubated with RNase (Sigma, Munich, Germany),
and stained with propidium iodide prior to FACScan
analysis (575 nm filter).
Mitochondrial membrane potential analysis
To analyze the mitochondrial membrane potential, the
MitoCapture Mitochondrial Apoptosis Detection Kit
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manufacturer’s instructions. For FACScan analysis, an
FL-1 setting (red fluorescence) at 575 nm and an FL-2
setting (green fluorescence) at 530 nm were used. Simi-
lar filters were used for fluorescence microscopy.
Western blot analysis
Western blot analysis was performed as recently
described [8]. Cell extracts were prepared with RIPA-
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP40,
0.5% doxycholine, 0.1% SDS), and 20 μgo fp r o t e i n
( B i o R a dB r a d f o r dA s s a y ,B i o R a d ,M ü n c h e n ,G e r m a n y )
was subjected to SDS-polyacrylamide gel electrophoresis.
Proteins were transferred to PVDF membranes in a
BioRad Mini Protean II Cell (BioRad, Munich, Germany)
at 1 mA/cm
2 membrane in 10% methanol, 192 mM gly-
cine, and 25 mM Tris, pH 8.2. Membranes were blocked
with 4% non-fat milk powder in PBS-0.05% Tween for 4
h. Primary antibodies were applied in blocking buffer
and incubated at room temperature overnight. Antibo-
dies against caspases and ER stress-related proteins were
included in antibody sampler kits purchased from Cell
Signalling, NEB, Frankfurt, Germany. Polyclonal antibo-
dies against PARP, bak, bid, bcl-XL, LC3, and COX IV
were purchased separately from Cell Signalling (NEB,
Frankfurt, Germany). Antibodies against ATF3, b-actin,
BiP, mcl-1, and p53 (DO1) were from SantaCruz Bio-
tech (Heidelberg, Germany). Monoclonal cell cycle regu-
latory antibodies were included in a cell cycle antibody
sampler kit from BD Biosciences, Heidelberg, Germany.
RT-PCR analysis
RNA was extracted from cells using the Nucleospin
RNA II kit (Macherey-Nagel, Düren, Germany). Reverse
transcription was performed with M-MLV reverse tran-
scriptase (Promega, Mannheim, Germany), as recom-
mended by the supplier. PCR was carried out in an
Eppendorf Mastercycler with GoTaq (Promega, Man-
nheim, Germany). Primer pairs (5’-3’ gccggctgtc
ctgccgctgc/tta cagtaaggctatcttattag) were used to amplify
a 402 bp C-terminal fragment of mcl-1 (MCL1S) and a
640 bp fragment (MCL1L). The difference between
MCL1S and MCL1L is generated by alternative splicing
within this region [16]. PCR cycling was performed after
a 5 min initiation at 94°C with 26-28 cycles of 1 min at
94°C, 1 min at 57°C, and 2 min at 72°C, followed by a 5
min extension at 72°C.
Mitochondria isolation
Cells were collected by centrifugation at 750 g for 5 min,
washed once with PBS (pH 7.4), and resuspended in five
volumes of buffer A (250 mM sucrose, 20 mM HEPES,
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 0.1 mM pefabloc, pH 7.5)
as described [20]. The cells were homogenized in a 2-ml
glass Dounce homogenizer (VWR, Darmstadt, Germany)
using the loose fit pestle for 4 strokes and the tight fit
pestle for an additional 10 strokes. The homogenates
were centrifuged at 750 g for 10 min at 4°C to remove
the nuclei. Supernatants were centrifuged at 10,000 g for
15 min at 4°C. The crude mitochondrial pellet fractions
were dissolved in Western blot sample buffer, and the
supernatants were mixed with 2× sample buffer. For
caspase cleavage analysis, enriched mitochondria were
resuspended in 20 μl of buffer A and incubated for 1 h
with 1 unit of recombinant human caspase 3 or caspase
8 (Millipore, Schwalbach, Germany).
Results
Nelfinavir induces apoptosis in human leukemia cells at
concentrations that have limited effects on normal bone
marrow cells
The human leukemia cell lines HL60 (promyelocytic
leukemia), IM9 (EBV-transformed B-lymphoblastoid cell
line) and Jurkat (T cell leukemia) were incubated with
nelfinavir at concentrations between 0 and 10 μg/ml.
Cell survival was then analyzed by a chemiluminescent
ATP assay (Fig. 1). At concentrations between 4 and 10
μg/ml, nelfinavir induced cell death in all three leukemia
cells tested, showing an ED50 (effective dose that
reduces ATP activity by 50%) of 5.6-7 μg/ml and an
ED90 of 9-10 μg/ml, depending on the cell line tested
(Table 1). In human bone marrow cells (BMC) tested ex
vivo under the same conditions, 10 μg/ml nelfinavir had
only a slight effect on cell survival. However, BMC were
not completely unaffected by nelfinavir, and higher nelfi-
navir concentrations (Table 1) were indeed able to
induce BMC cell death. In leukemia cells treated with 8
μg/ml nelfinavir, phase contrast microscopy revealed
extensive intracellular vacuole formation (Fig. 1), which
was absent in BMC treated with the same nelfinavir
concentration. To analyze the nature of nelfinavir-
mediated cell death, a propidium iodide permeability
(PI) and annexin binding assay was performed. FACScan
analysis showed that a concentration of 8 μg/ml nelfina-
vir induced a significant increase in the number of
apoptotic (annexin-positive) and necrotic or dead (PI-
permeable) leukemia cells (Fig. 1), but had no detectable
effects on the morphology or apoptosis of the rather
heterogeneous BMC cell population (Fig. 1).
Nelfinavir downregulates cyclin B and cdk1 expression
and interferes with cell cycle progression
It has previously been shown by both our group [8] and
others [1,2] that nelfinavir induces the endoplasmic reti-
culum stress response in solid human cancer cells,
resulting in upregulation of BiP, phosphorylation of
eIF2, upregulation of ATF3, and autophagy. In contrast
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analysis did not shown upregulation of BiP or ATF3 in
nelfinavir-treated leukemia cells, and cells exhibited no
signs of autophagy as shown by a lack of LC3B upregu-
lation (Fig. 2A). However, nelfinavir induced a slight
increase in eIF2 phosphorylation (Fig. 2A), suggesting
an influence on cell cycle progression, which was further
indicated by reduced expression of cyclin B and cdk1
(Fig. 2A). Cell cycle analysis by FACScan revealed a
reduced G2/M peak, suggesting interference with cell
cycle progression (Fig. 2B). However, the most promi-
nent effect of nelfinavir appeared to be the induction of
apoptosis, as indicated by a significant increase in the
number of cells in the sub-G1 phase (Fig. 2B).
Nelfinavir induces caspase activation and mcl-1
upregulation despite partial caspase 8-mediated mcl-1
cleavage
To gain better insight into the mechanism by which nel-
finavir induced apoptosis and the extent of caspase
involvement, we performed Western blot analysis for
several apoptosis-related proteins. In accordance with
the FACS analyses presented in Figs. 1 and 2B, induc-
tion of apoptosis by nelfinavir was confirmed by clea-
vage of PARP, a specific substrate of effector caspases 3
and 7, whose activation is shown by the appearance of
their specific cleavage products (Fig. 3A). Caspases 3
and 7 are cleaved and activated by initiator caspase 9.
Caspase 9 cleavage was observed in nelfinavir-treated
Figure 2 Influence of nelfinavir on cell cycle progression and
apoptosis in human leukemia cells. IM9 and Jurkat cells were
treated for 24 h with 8 μg/ml nelfinavir and analyzed by (A)
Western blot analysis for the expression of cell stress- and cell cycle-
related proteins and by (B) FACScan analysis for cell cycle
distribution of nelfinavir-treated IM9 cells.
Table 1 Effective drug doses for nelfinavir-mediated cell
death [μg/ml]
HL60 Jurkat IM9 BMC
ED50 5.6 5.8 7 15.2
ED80 8.9 7.8 9.3 23
ED90 9.8 9 10 N.D.
Figure 1 Nelfinavir induces cell death in leukemia cells.T h eh u m a nl e u k e m i ac e l ll i n e sH L 6 0 ,J u r k a t ,a n dI M 9 ,a n da nex vivo sample of
human bone marrow cells (BMC) were treated for 48 h in cell culture with the indicated concentrations of nelfinavir and analyzed by a
chemiluminescent ATP assay for cell survival (A), by annexin/PI staining [FL-1 (propidium iodide): 575 nm; FL-2 (FITC): 530 nm] for the occurrence
of apoptosis and necrosis (B), and by phase contrast microscopy for morphological changes (C). For FACScan analysis and phase contrast
microscopy, all cells were treated equally for 24 h with 8 μg/ml nelfinavir.
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were rather faint (Fig. 3A). In contrast, significant acti-
vation of initiator caspase 8 was observed, suggesting
potential involvement of an additional, mitochondria-
independent apoptotic pathway. Activation of caspase
12, an initiator caspase downstream of ER stress, was
not detected by Western blot analysis (Fig. 3A).
To further investigate the mechanism leading to nelfi-
navir-induced apoptosis, the expression of several apop-
tosis-regulatory proteins was analyzed. Nelfinavir did
not increase the expression of p53 in IM9 cells (Fig.
3A). In addition, the expression of the small bcl family
members, bak, bcl-XL and bcl2, appeared to be
unchanged (Fig. 3A). Unexpectedly, however, we
observed an upregulation of the anti-apoptotic mcl-1
protein in nelfinavir-treated cancer cells (Fig. 3A). Upre-
gulation of mcl-1 by nelfinavir occurred in leukemia
cells, but not in bone marrow fibroblasts (BMF) gener-
ated from bone mesenchymal marrow cells by cell cul-
ture propagation (Fig. 3B). In addition to the
accumulation of full-length mcl-1 (43 kDa), shorter mcl-
1 immunoreactive bands appeared in nelfinavir-treated
leukemia cells (Fig. 3A, B), representing either splice
variants or cleavage products of mcl-1. To distinguish
the relative expression levels of the mcl-1 splice variants,
we performed RT-PCR analysis, which revealed that
anti-apoptotic mcl-1L is the most prominent form
expressed by leukemia cells. In contrast, the pro-apopto-
tic mcl-1S form, generated by internal alternative spli-
cing, was poorly expressed and was not upregulated by
nelfinavir treatment (Fig. 4A). In order to demonstrate
that the shorter forms of mcl-1 could represent mcl-1
cleavage products and not the splice variant mcl-1S,
mitochondria enriched by cellular subfractionation of
IM9 cells were prepared and incubated with recombi-
nant caspase 3 and caspase 8. The addition of purified
caspase 8 but not caspase 3 to the mitochondria
resulted in the formation of mcl-1 cleavage products
that were identical to those obtained by incubation of
viable IM9 cells with nelfinavir (Fig. 4B). Thus, the addi-
tional bands presenting mcl-1 immunoreactivity
observed after nelfinavir treatment represent mcl-1L
degradation products and not the pro-apoptotic short
splice form of mcl-1, mcl-1S.
Nelfinavir induces mitochondria protection in leukemia
cells
In standard apoptotic conditions, pro-apoptotic bcl-2
family members such as bak or t-bid insert into the
outer mitochondrial membrane and induce pore for-
mation, resulting in the efflux of mitochondrial pro-
teins such as cytochrome c and smac/DIABLO. The
efflux of smac into the cytosol can be monitored
experimentally by cell fractionation studies. In IM9
cells, the classical apoptosis-inducer staurosporine
caused an accumulation of smac in the cytosol, accom-
panied by downregulation of mcl-1 (Fig. 4C). In con-
trast, nelfinavir treatment of IM9 cells enhanced
mitochondrial mcl-1 expression and had no effect on
the cellular distribution of smac (Fig. 4C). These
results were confirmed usingaf l u o r e s c e n tm i t o c h o n -
dria tracker dye that accumulates within intact mito-
chondria as a red-fluorescent dye or within the cytosol
as a monomer that exhibits green fluorescence. Both
FACScan and fluorescence analysis showed that the
mitochondrial membrane potential of IM9 cells is dis-
rupted by staurosporine but not by nelfinavir treat-
ment (Fig. 5). Even more, the percentage of cells with
Figure 3 Nelfinavir induces activation of caspase 3 and caspase 8 despite mcl-1 upregulation. IM9, Jurkat and bone marrow fibroblast
cells (BMF) were treated for 24 h with 8 μg/ml nelfinavir and analyzed by Western blot analysis for the expression of caspases and apoptosis-
relevant proteins. (A) and (B): cell lysates of IM9 and Jurkat cells; (C) cell lysates of IM9 and BMF.
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be increased after nelfinavir treatment (Fig. 5). A time-
dependent analysis of the expression of pro- and anti-
apoptotic proteins in nelfinavir-treated IM9 cells
revealed a rather immediate upregulation of mcl-1
after nelfinavir treatment, and a continuous and
obviously concomitant increase in caspase and PARP
cleavage products (Fig. 4D). At later stages of apopto-
sis, the 36 kDa mcl-1 cleavage product appeared to
be further converted into a 32 kDa cleavage product
(Fig. 4D).
Sorafenib downregulates mcl-1 expression and enhances
nelfinavir-mediated cell death of leukemia cells
Because the previous experiments revealed that nelfina-
vir induced a mitochondria-independent apoptotic path-
way, we tested whether pharmacological downregulation
of mcl-1 could further enhance the cytotoxic effect of
nelfinavir on leukemia cells by additionally activating
the mitochondrial pathway. The multikinase inhibitor
sorafenib, an approved drug for the treatment of renal
cancer, has been shown to downregulate the expression
of mcl-1 at both the transcriptional and posttranscrip-
tional level [21]. Fig. 6A shows that at a concentration
of 2 μg/ml, sorafenib efficiently reduced mcl-1 expres-
sion in HL60 cells, with little effect on bcl-2 expression.
When combined with 5 μg/ml nelfinavir, a concentra-
tion that inefficiently induces cell death when applied
alone (Fig. 6B), sorafenib significantly enhanced the effi-
cacy of nelfinavir. In addition, FACScan analysis showed
that sorafenib alone or in combination with nelfinavir
leads to a loss of outer mitochondrial membrane poten-
tial (Fig. 6C). To exclude the possibility that this drug
combination is potentially myelosuppressive, we tested
nelfinavir in combination with sorafenib on bone mar-
row cells ex vivo. The same dose of nelfinavir and sora-
fenib that caused significant cell death in leukemia cells
had only limited effects on bone marrow cells (Fig. 6B).
Discussion
Mcl-1 is a crucial regulator of cell death in leukemia
cells [18]. Overexpression of mcl-1 can inhibit cell death
by stabilizing the outer mitochondrial membrane poten-
tial [9-14], and several recent leukemia treatment strate-
gies have attempted to target the expression of mcl-1 by
either pharmacological inhibition or siRNA-mediated
downregulation [22]. Our investigations show that nelfi-
navir, despite its ability to induce death of leukemia
Figure 4 Nelfinavir induces mitochondria protection despite caspase 8-mediated mcl-1 cleavage. A) The indicated leukemia cell lines
were treated with 8 μg/ml nelfinavir for 24 h hours and subjected to PCR analysis to detect potential mcl-1 splice forms and transcriptional mcl-
1 regulation. B) An enriched cellular mitochondria fraction of IM9 cells was treated with recombinant caspase 3 or caspase 8 as indicated and
subjected to Western blot analysis for mcl-1 expression. Whole cell extracts of nelfinavir-treated IM9 cells were run in parallel for comparison. C)
IM9 cells treated for 24 h with 8 μg/ml nelfinavir or 500 nM staurosporine were separated into a crude mitochondria fraction (M) and a crude
cytosol fraction (C) and analyzed by Western blot for the distribution of mcl-1, smac and mitochondria-resident protein cytochrome c oxidase
(COX IV). For direct comparison, mcl-1 and COX IV immunostaining were performed on the same blot. Staining intensities were analyzed with a
BioRad gel documentation system using the BioRad Quantity One program (BioRad, Munich, Germany) and expressed as relative expression
values. D) IM9 cells were treated with 10 μg/ml nelfinavir for the indicated times and analyzed by Western blot analysis. Selected bands (mcl1:
43, 36, 32 kDa; caspase 3: 17+19 kDa; caspase 8: 18 kDa) were densitometrically analyzed using the BioRad Quantity One program and plotted as
relative expression values versus b-actin expression.
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1 protein in human leukemia cells that might stabilize
the mitochondria even under apoptotic conditions.
Because we did not observe increased mcl-1 mRNA
expression by RT-PCR analysis, and the mcl-1 protein
was upregulated within hours, mcl-1 is probably stabi-
lized by posttranscriptional mechanisms. We have
recently shown that the mcl-1 protein can be stabilized
in solid cancer cells by ERK1/2-mediated protein phos-
phorylation [23]. However, we could not detect activa-
tion of this pathway in leukemia cells (data not shown),
suggesting that other mcl-1 protein stabilization
mechanisms may function in leukemia cells.
Nelfinavir has previously been observed to have both
cell- and tissue-protective effects on various human
and murine cells and tissues [24-27]. For example, in
contrast to the pro-apoptotic effect of nelfinavir on
leukemia cells, it is cytoprotective for murine liver
cells [25], neurons [25], retina cells [26], and pancreas
cells [27]. Interestingly, the cytoprotective effect of nel-
finavir has already been associated with mitochondria
protection [24,25]. Upregulation of mcl-1 could be
involved in nelfinavir-mediated cytoprotection of sev-
eral untransformed cell types, although we did not
observe significant endogenous mcl-1 expression or
Figure 5 Nelfinavir-induced cell death is independent of mitochondrial membrane depolarization. IM9 cells were treated for 24 h with 8
μg/ml nelfinavir or 500 nM staurosporine and the outer mitochondrial membrane potential was analyzed using the MitoCapture kit (Alexis,
Lörrach, Germany) by either FACScan analysis or fluorescence microscopy.
Figure 6 Sorafenib enhances the efficacy of nelfinavir-induced
cell death by mcl-1 downregulation. A) HL60 cells were treated
with 5 μg/ml nelfinavir or 2 μg/ml sorafenib either alone or in
combination, and analyzed after 24 h for the expression of
apoptosis-related proteins by Western blot analysis. B) HL60 cells
and ex vivo bone marrow cells (BMC) were incubated using the
same conditions as in (A) and analyzed after 48 h for total cell
survival by an ATP assay. C) HL60 and Jurkat cells were treated with
either 5 μg/ml nelfinavir or 2 μg/ml sorafenib either alone or in
combination, and the outer mitochondrial membrane potential was
analyzed after 24 h by FACScan analysis.
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marrow fibroblasts (Fig. 2) or leukocytes (data not
shown). In some previous studies, the mitochondria-
protective effect of nelfinavir was found to be indepen-
dent of protein synthesis [24] and to be mediated by
direct binding of nelfinavir to the adenine nucleotide
translocase (ANT) [24,25], a subunit of the mitochon-
drial permeability transition pore complex [28,29].
Thus, nelfinavir-mediated mitochondria-protection and
cell death can be modulated by various mechanisms
that might vary among cell types and species. Interest-
ingly, a similar paradoxical effect has been observed
for glucocorticoids (dexamethasone), which induce
apoptosis in leukemia cells but protect normal and
cancerous epithelial cells by upregulating anti-apopto-
tic proteins [30,31]. However, the prospect of nelfinavir
as a multipotent cytoprotective agent with selective
anti-cancer activity should be considered with caution
and may be an unachievable benchmark for this drug.
We have observed that higher doses of nelfinavir can
indeed induce cell damage in human bone marrow
cells (Table 1) and, thus, nelfinavir should not be
regarded as a bone marrow-protective drug. Still, the
nelfinavir concentration necessary to induce high levels
of apoptosis in leukemia cells showed only a limited
effect on bone marrow cells, thus providing a potential
therapeutic concentration for efficient leukemia treat-
ment with reduced adverse effects on the bone mar-
row. This is especially important given that the bone
marrow is already damaged in leukemia patients after
standard first- and second-line high dose chemothera-
pies with myelosuppressive drugs.
These data, as well other reports, indicate that the
concentration of nelfinavir appears to be of crucial
importance for its effect as either a cytoprotective drug
or a cell death-inducing agent. In HIV-infected persons
treated with nelfinavir, individual nelfinavir plasma
concentrations were found to be highly variable, with a
mean average drug plasma concentration of 2.22 ±
1.25 μg/m [32]. This level is below the concentration
that induces death of leukemia cells or other cancer
cells. In fact, a recent study on the occurrence of can-
cer in nelfinavir-treated HIV patients revealed no
reduced cancer risk [33], confirming that these con-
centrations are sub-optimal for cancer treatment.
H o w e v e r ,t h ep l a s m ac o n c e n t r a t i o n so c c u r r i n gi nH I V
patients have been specifically adapted for efficient and
long term HIV protease inhibition. Administering
higher oral doses of nelfinavir or applying nelfinavir
via an intravenous route can significantly enhance
plasma nelfinavir concentrations [34]. Further, and
more likely in the potential clinical use of nelfinavir
for cancer therapy, efficient combination treatments
with other drugs may allow the effective concentration
of nelfinavir to be reduced, as shown in the present in
vitro study through the combination of nelfinavir and
sorafenib.
Conclusions
The results obtained by our group and others show that
nelfinavir could become a potential and valuable new
anti-cancer drug, not only because of its anti-cancer
effects in vitro and in vivo, but also because of its pro-
ven pharmacological history and known and tolerable
side effects [35,36]. Therefore, we strongly recommend
clinical studies with nelfinavir in leukemia patients, pre-
ferentially in combination with sorafenib.
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